Tempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business Update
Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement ...
Tempest Reports Year End 2024 Financial Results and Provides Business Update
Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with ...
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) ...
CURE19h
Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...
Public Broadcasting Service (PBS)12h
FTC commissioner fired by Trump says move threatens agency designed to protect consumers
Two Democratic commissioners of the Federal Trade Commission sued the Trump administration after being fired before their ...
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine , Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild ...
Zacks Investment Research on MSN22h
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
Ionis Pharmaceuticals IONS signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive ...